(via TheNewswire)
Anabasis Pharma Israelis aimed at developing a novel Drug Delivery System combined with proprietary formulation based on Psilocybin Active Pharmaceutical Ingredient, the focus of the development is therapy of Depression in Patients with Dementia. Anabasis will use license proven formulation and drug delivery technology to reduce cost, time and risk of developing psilocybin treatment for depression in patients with dementia
Anabasis Pharma Israelhas partnered with Marina which is the biggest Mushroom grower and distributor in
Anabasis Pharma Israelis led by seasoned managers, scientific team and directors from the pharma industry including:
Prof.
Prof.
With the commencement of operations, the Company is no longer considered to be a “shell company” pursuant as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934.
The Company also announced that it has changed its name to
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "should," "intends," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the
###
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source